ACADIA Pharmaceuticals Inc.
ACAD
Rang în acțiuni
#4508
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Preț acțiune
$19.76
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$3.40B
Schimbare (1 zi)
3.32%
Schimbare (1 an)
-5.66%
Țară
US
Tranzacționează ACADIA Pharmaceuticals Inc. (ACAD)
Categorie
Healthcare
Câștiguri pentru ACADIA Pharmaceuticals Inc. (ACAD)
Câștiguri în Jun 2026 TTM: $121.37M
Conform celor mai recente rapoarte financiare ale ACADIA Pharmaceuticals Inc., câștigurile actuale ale companiei sunt $121.37M. În anul 2023, compania a înregistrat un câștig de $-51.04M, o creștere față de câștigului din 2022, care a fost de $-213.44M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru ACADIA Pharmaceuticals Inc. din 2000 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $121.37M | -52.97% |
| 2024 | $258.08M | -605.67% |
| 2023 | $-51.04M | -76.09% |
| 2022 | $-213.44M | 27.41% |
| 2021 | $-167.52M | -40.38% |
| 2020 | $-280.97M | 19.88% |
| 2019 | $-234.38M | -3.92% |
| 2018 | $-243.94M | -15.38% |
| 2017 | $-288.28M | 6.75% |
| 2016 | $-270.05M | 64.55% |
| 2015 | $-164.11M | 77.47% |
| 2014 | $-92.48M | 143.69% |
| 2013 | $-37.95M | 82.01% |
| 2012 | $-20.85M | -8.42% |
| 2011 | $-22.77M | -250.37% |
| 2010 | $15.14M | -133.53% |
| 2009 | $-45.15M | -29.73% |
| 2008 | $-64.24M | 13.93% |
| 2007 | $-56.39M | 25.18% |
| 2006 | $-45.05M | 31.97% |
| 2005 | $-34.14M | 31.71% |
| 2004 | $-25.92M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | 4,246.20% |
US
|
|
| $-3.09B | -2,643.50% |
US
|
|
| $-4.02B | -3,409.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,507.22% |
NL
|
